Somatostatin Analogs Market- Global Industry Analysis and forecast 2022- 2029: By Type, Treatment, and Region


Somatostatin Analogs Market is expected to grow at a CAGR of 7.3% during the forecast period and is expected to reach US$ 12.15 Bn by 2029.

Somatostatin Analogs Market

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of Market leaders, Market followers, and Market disrupters in the report, and the same is reflected in our analysis.

Somatostatin Analogs Market Definition:

Somatostatin Analogs are the artificial version of Somatostatin that helps control the excessive secretion of hormones, especially the growth hormone and serotonin in the human body. It is commonly used to treat Neuroendocrine Tumors (NETs) and Acromegaly, a rare hormonal disorder, and other such hormonal disorders.

Somatostatin Analogs Market Dynamics:

An increase in the R&D activities in the Somatostatin analogs market is having a positive impact on market growth. A number of studies are being conducted for further research and advancement in the already existing drug molecules. The number of patients diagnosed with Neuroendocrine Tumors (NETs) is increasing each year. This creates a demand to develop improved treatments ultimately resulting in the market growth. World Alliance of Pituitary Organizations (WAPO) has launched a global awareness campaign to increase awareness about Acromegaly and the role of Somatostatin analogs in its treatment. The participation of some major market players gives a further boost to the market.

Somatostatin Analogs Market Segmentation:

The report covers the segments in the Somatostatin Analogs Market such as type and treatment. Based on type, the market size of Octreotide was valued at USD 5.7 Billion in 2019 and is expected to grow at a CAGR of XX% over the forecast period. It was the first and foremost type of Somatostatin analog and is mostly used to treat hormonal disorders. Pasireotide market is anticipated to be the fastest-growing given the fact that awareness regarding Cushing’s syndrome is increasing and hence is the treatment.

Somatostatin Analogs Market Region-wise Analysis:

North America Somatostatin Analogs Market was valued at US$ xx Mn. in 2019 and is expected to reach a value of US$ xx Mn. by 2027, with a CAGR of xx % during the forecast period. The region will retain its market dominance in the future because of the increased awareness and expenditure on healthcare. The emergence of new companies and the development of improved drugs have also contributed to the market growth in North America.

Country-wise Analysis:

The rise in spending for healthcare and many new cases registered by the US, Canada, and many Southeast Asian countries has led to an increase in the demand for the Somatostatin Analogs market. The Market in the APAC is projected to register comparatively faster growth in terms of revenue in the future.

Competitive Landscape:

The competitive landscape section in the Somatostatin Analogs Market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects of the companies having a stronghold in the Somatostatin Analogs Market. In 2014, Pasireotide experienced the highest sales for treating acromegaly. Now it is under phase II clinical trials for advanced/metastatic hepatocellular carcinoma.

The objective of the report is to present a comprehensive analysis of the Global Somatostatin Analogs Market including all the stakeholders of the industry. The past and current status of the industry with the forecasted Market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes Market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Somatostatin Analogs Market dynamics, structure by analyzing the Market segments and projects the Global Somatostatin Analogs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Somatostatin Analogs Market make the report investor’s guide.

Somatostatin Analogs Market Scope: Inquiry Before Buying


Somatostatin Analogs Market, by Type

• Octreotide
• Lanreotide
• Pasireotide

Somatostatin Analogs Market, Treatment

• Neuroendocrine Tumor (NET)
• Carcinoid Syndrome
• Acromegaly
• Cushing’s Syndrome
• Others

Somatostatin Analogs Market, By Region

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Somatostatin Analogs Market Key players

• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Midatech Pharma PLC
• Ipsen Pharma
• Chiasma, Inc.
• Peptron, Inc.
• Crinetics Pharmaceuticals
• Dauntless Pharmaceuticals
• Camurus AB
• Teva Pharmaceuticals Inc.
• Pfizer Inc
• Fresenius Kabi
• Mylan N.V.
• SAGENT Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Recordati Rare Diseases.
• Hybio Pharmaceutical Co., Ltd.
• Lonza Group AG
• Teijin Pharma Limited
• Fresenius Kabi

Frequently Asked Questions:

1. Which region has the largest share in Global Somatostatin Analogs Market Market?
Ans: Asia Pacific region holds the highest share in 2021.

2. What is the growth rate of Global Somatostatin Analogs Market Market?
Ans: The Global Somatostatin Analogs Market Market is growing at a CAGR of 7.3% during forecasting period 2022-2029.

3. What is scope of the Global Somatostatin Analogs Market market report?
Ans: Global Somatostatin Analogs Market Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Somatostatin Analogs Market market?
Ans: The important key players in the Global Somatostatin Analogs Market Market are – Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pfizer Inc, Fresenius Kabi, Mylan N.V., SAGENT Pharmaceuticals, Hikma Pharmaceuticals PLC, Recordati Rare Diseases., Hybio Pharmaceutical Co., Ltd., Lonza Group AG, Teijin Pharma Limited, and Fresenius Kabi

5. What is the study period of this market?
Ans: The Global Somatostatin Analogs Market Market is studied from 2021 to 2029. 




Global Somatostatin Analogs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Somatostatin Analogs Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Somatostatin Analogs Market Analysis and Forecast
6.1. Somatostatin Analogs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Somatostatin Analogs Market Analysis and Forecast, by Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Somatostatin Analogs Market Value Share Analysis, by Type
7.4. Somatostatin Analogs Market Size (US$ Bn) Forecast, by Type
7.5. Somatostatin Analogs Market Analysis, by Type
7.6. Somatostatin Analogs Market Attractiveness Analysis, by Type

8. Global Somatostatin Analogs Market Analysis and Forecast, By Treatment
8.1. Introduction and Definition
8.2. Key Findings
8.3. Somatostatin Analogs Market Value Share Analysis, By Treatment
8.4. Somatostatin Analogs Market Size (US$ Bn) Forecast, By Treatment
8.5. Somatostatin Analogs Market Analysis, By Treatment
8.6. Somatostatin Analogs Market Attractiveness Analysis, By Treatment

9. Global Somatostatin Analogs Market Analysis, by Region
9.1. Somatostatin Analogs Market Value Share Analysis, by Region
9.2. Somatostatin Analogs Market Size (US$ Bn) Forecast, by Region
9.3. Somatostatin Analogs Market Attractiveness Analysis, by Region

10. North America Somatostatin Analogs Market Analysis
10.1. Key Findings
10.2. North America Somatostatin Analogs Market Overview
10.3. North America Somatostatin Analogs Market Value Share Analysis, by Type
10.4. North America Somatostatin Analogs Market Forecast, by Type
10.4.1. Octreotide
10.4.2. Lanreotide
10.4.3. Pasireotide
10.4.4. Other
10.5. North America Somatostatin Analogs Market Value Share Analysis, By Treatment
10.6. North America Somatostatin Analogs Market Forecast, By Treatment
10.6.1. Neuroendocrine Tumor (NET)
10.6.2. Carcinoid Syndrome
10.6.3. Acromegaly
10.6.4. Cushing’s Syndrome
10.6.5. Others
10.7. North America Somatostatin Analogs Market Value Share Analysis, by Country
10.8. North America Somatostatin Analogs Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Somatostatin Analogs Market Analysis, by Country
10.10. U.S. Somatostatin Analogs Market Forecast, by Type
10.10.1. Octreotide
10.10.2. Lanreotide
10.10.3. Pasireotide
10.10.4. Others
10.11. U.S. Somatostatin Analogs Market Forecast, By Treatment
10.11.1. Neuroendocrine Tumor (NET)
10.11.2. Carcinoid Syndrome
10.11.3. Acromegaly
10.11.4. Cushing’s Syndrome
10.11.5. Other
10.12. Canada Somatostatin Analogs Market Forecast, by Type
10.12.1. Octreotide
10.12.2. Lanreotide
10.12.3. Pasireotide
10.12.4. Others
10.13. Canada Somatostatin Analogs Market Forecast, By Treatment
10.13.1. Neuroendocrine Tumor (NET)
10.13.2. Carcinoid Syndrome
10.13.3. Acromegaly
10.13.4. Cushing’s Syndrome
10.13.5. Other
10.14. North America Somatostatin Analogs Market Attractiveness Analysis
10.14.1. By Type
10.14.2. By Treatment
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Developments

11. Europe Somatostatin Analogs Market Analysis
11.1. Key Findings
11.2. Europe Somatostatin Analogs Market Overview
11.3. Europe Somatostatin Analogs Market Value Share Analysis, by Type
11.4. Europe Somatostatin Analogs Market Forecast, by Type
11.4.1. Octreotide
11.4.2. Lanreotide
11.4.3. Pasireotide
11.4.4. Others
11.5. Europe Somatostatin Analogs Market Value Share Analysis, By Treatment
11.6. Europe Somatostatin Analogs Market Forecast, By Treatment
11.6.1. Neuroendocrine Tumor (NET)
11.6.2. Carcinoid Syndrome
11.6.3. Acromegaly
11.6.4. Cushing’s Syndrome
11.6.5. Other
11.7. Europe Somatostatin Analogs Market Value Share Analysis, by Country
11.8. Europe Somatostatin Analogs Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Somatostatin Analogs Market Analysis, by Country
11.10. Germany Somatostatin Analogs Market Forecast, by Type
11.10.1. Octreotide
11.10.2. Lanreotide
11.10.3. Pasireotide
11.10.4. Others
11.11. Germany Somatostatin Analogs Market Forecast, By Treatment
11.11.1. Neuroendocrine Tumor (NET)
11.11.2. Carcinoid Syndrome
11.11.3. Acromegaly
11.11.4. Cushing’s Syndrome
11.11.5. Other
11.12. U.K. Somatostatin Analogs Market Forecast, by Type
11.12.1. Octreotide
11.12.2. Lanreotide
11.12.3. Pasireotide
11.12.4. Others
11.13. U.K. Somatostatin Analogs Market Forecast, By Treatment
11.13.1. Neuroendocrine Tumor (NET)
11.13.2. Carcinoid Syndrome
11.13.3. Acromegaly
11.13.4. Cushing’s Syndrome
11.13.5. Other
11.14. France Somatostatin Analogs Market Forecast, by Type
11.14.1. Octreotide
11.14.2. Lanreotide
11.14.3. Pasireotide
11.14.4. Others
11.15. France Somatostatin Analogs Market Forecast, By Treatment
11.15.1. Neuroendocrine Tumor (NET)
11.15.2. Carcinoid Syndrome
11.15.3. Acromegaly
11.15.4. Cushing’s Syndrome
11.15.5. Other
11.16. Italy Somatostatin Analogs Market Forecast, by Type
11.16.1. Octreotide
11.16.2. Lanreotide
11.16.3. Pasireotide
11.16.4. Others
11.17. Italy Somatostatin Analogs Market Forecast, By Treatment
11.17.1. Neuroendocrine Tumor (NET)
11.17.2. Carcinoid Syndrome
11.17.3. Acromegaly
11.17.4. Cushing’s Syndrome
11.17.5. Other
11.18. Spain Somatostatin Analogs Market Forecast, by Type
11.18.1. Octreotide
11.18.2. Lanreotide
11.18.3. Pasireotide
11.18.4. Others
11.19. Spain Somatostatin Analogs Market Forecast, By Treatment
11.19.1. Neuroendocrine Tumor (NET)
11.19.2. Carcinoid Syndrome
11.19.3. Acromegaly
11.19.4. Cushing’s Syndrome
11.19.5. Other
11.20. Rest of Europe Somatostatin Analogs Market Forecast, by Type
11.20.1. Octreotide
11.20.2. Lanreotide
11.20.3. Pasireotide
11.20.4. Others
11.21. Rest of Europe Somatostatin Analogs Market Forecast, By Treatment
11.21.1. Neuroendocrine Tumor (NET)
11.21.2. Carcinoid Syndrome
11.21.3. Acromegaly
11.21.4. Cushing’s Syndrome
11.21.5. Other
11.22. Europe Somatostatin Analogs Market Attractiveness Analysis
11.22.1. By Type
11.22.2. By Treatment
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Developments

12. Asia Pacific Somatostatin Analogs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Somatostatin Analogs Market Overview
12.3. Asia Pacific Somatostatin Analogs Market Value Share Analysis, by Type
12.4. Asia Pacific Somatostatin Analogs Market Forecast, by Type
12.4.1. Octreotide
12.4.2. Lanreotide
12.4.3. Pasireotide
12.4.4. Others
12.5. Asia Pacific Somatostatin Analogs Market Value Share Analysis, By Treatment
12.6. Asia Pacific Somatostatin Analogs Market Forecast, By Treatment
12.6.1. Neuroendocrine Tumor (NET)
12.6.2. Carcinoid Syndrome
12.6.3. Acromegaly
12.6.4. Cushing’s Syndrome
12.6.5. Other
12.7. Asia Pacific Somatostatin Analogs Market Value Share Analysis, by Country
12.8. Asia Pacific Somatostatin Analogs Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Somatostatin Analogs Market Analysis, by Country
12.10. China Somatostatin Analogs Market Forecast, by Type
12.10.1. Octreotide
12.10.2. Lanreotide
12.10.3. Pasireotide
12.10.4. Others
12.11. China Somatostatin Analogs Market Forecast, By Treatment
12.11.1. Neuroendocrine Tumor (NET)
12.11.2. Carcinoid Syndrome
12.11.3. Acromegaly
12.11.4. Cushing’s Syndrome
12.11.5. Other
12.12. India Somatostatin Analogs Market Forecast, by Type
12.12.1. Octreotide
12.12.2. Lanreotide
12.12.3. Pasireotide
12.12.4. Others
12.13. India Somatostatin Analogs Market Forecast, By Treatment
12.13.1. Neuroendocrine Tumor (NET)
12.13.2. Carcinoid Syndrome
12.13.3. Acromegaly
12.13.4. Cushing’s Syndrome
12.13.5. Other
12.14. Japan Somatostatin Analogs Market Forecast, by Type
12.14.1. Octreotide
12.14.2. Lanreotide
12.14.3. Pasireotide
12.14.4. Others
12.15. Japan Somatostatin Analogs Market Forecast, By Treatment
12.15.1. Neuroendocrine Tumor (NET)
12.15.2. Carcinoid Syndrome
12.15.3. Acromegaly
12.15.4. Cushing’s Syndrome
12.15.5. Other
12.16. ASEAN Somatostatin Analogs Market Forecast, by Type
12.16.1. Octreotide
12.16.2. Lanreotide
12.16.3. Pasireotide
12.16.4. Others
12.17. ASEAN Somatostatin Analogs Market Forecast, By Treatment
12.17.1. Neuroendocrine Tumor (NET)
12.17.2. Carcinoid Syndrome
12.17.3. Acromegaly
12.17.4. Cushing’s Syndrome
12.17.5. Other
12.18. Rest of Asia Pacific Somatostatin Analogs Market Forecast, by Type
12.18.1. Octreotide
12.18.2. Lanreotide
12.18.3. Pasireotide
12.18.4. Others
12.19. Rest of Asia Pacific Somatostatin Analogs Market Forecast, By Treatment
12.19.1. Neuroendocrine Tumor (NET)
12.19.2. Carcinoid Syndrome
12.19.3. Acromegaly
12.19.4. Cushing’s Syndrome
12.19.5. Other
12.20. Asia Pacific Somatostatin Analogs Market Attractiveness Analysis
12.20.1. By Type
12.20.2. By Treatment
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Developments

13. Middle East & Africa Somatostatin Analogs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Somatostatin Analogs Market Overview
13.3. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, by Type
13.4. Middle East & Africa Somatostatin Analogs Market Forecast, by Type
13.4.1. Octreotide
13.4.2. Lanreotide
13.4.3. Pasireotide
13.4.4. Others
13.5. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, By Treatment
13.6. Middle East & Africa Somatostatin Analogs Market Forecast, By Treatment
13.6.1. Neuroendocrine Tumor (NET)
13.6.2. Carcinoid Syndrome
13.6.3. Acromegaly
13.6.4. Cushing’s Syndrome
13.6.5. Other
13.7. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, by Country
13.8. Middle East & Africa Somatostatin Analogs Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Somatostatin Analogs Market Analysis, by Country
13.10. GCC Somatostatin Analogs Market Forecast, by Type
13.10.1. Octreotide
13.10.2. Lanreotide
13.10.3. Pasireotide
13.10.4. Others
13.11. GCC Somatostatin Analogs Market Forecast, By Treatment
13.11.1. Neuroendocrine Tumor (NET)
13.11.2. Carcinoid Syndrome
13.11.3. Acromegaly
13.11.4. Cushing’s Syndrome
13.11.5. Other
13.12. South Africa Somatostatin Analogs Market Forecast, by Type
13.12.1. Octreotide
13.12.2. Lanreotide
13.12.3. Pasireotide
13.12.4. Others
13.13. South Africa Somatostatin Analogs Market Forecast, By Treatment
13.13.1. Neuroendocrine Tumor (NET)
13.13.2. Carcinoid Syndrome
13.13.3. Acromegaly
13.13.4. Cushing’s Syndrome
13.13.5. Other
13.14. Rest of Middle East & Africa Somatostatin Analogs Market Forecast, by Type
13.14.1. Octreotide
13.14.2. Lanreotide
13.14.3. Pasireotide
13.14.4. Others
13.15. Rest of Middle East & Africa Somatostatin Analogs Market Forecast, By Treatment
13.15.1. Neuroendocrine Tumor (NET)
13.15.2. Carcinoid Syndrome
13.15.3. Acromegaly
13.15.4. Cushing’s Syndrome
13.15.5. Other

13.16. Middle East & Africa Somatostatin Analogs Market Attractiveness Analysis
13.16.1. By Type
13.16.2. By Treatment
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Developments

14. South America Somatostatin Analogs Market Analysis
14.1. Key Findings
14.2. South America Somatostatin Analogs Market Overview
14.3. South America Somatostatin Analogs Market Value Share Analysis, by Type
14.4. South America Somatostatin Analogs Market Forecast, by Type
14.4.1. Octreotide
14.4.2. Lanreotide
14.4.3. Pasireotide
14.4.4. Others
14.5. South America Somatostatin Analogs Market Value Share Analysis, By Treatment
14.6. South America Somatostatin Analogs Market Forecast, By Treatment
14.6.1. Neuroendocrine Tumor (NET)
14.6.2. Carcinoid Syndrome
14.6.3. Acromegaly
14.6.4. Cushing’s Syndrome
14.6.5. Other

14.7. South America Somatostatin Analogs Market Value Share Analysis, by Country
14.8. South America Somatostatin Analogs Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Somatostatin Analogs Market Analysis, by Country
14.10. Brazil Somatostatin Analogs Market Forecast, by Type
14.10.1. Octreotide
14.10.2. Lanreotide
14.10.3. Pasireotide
14.10.4. Others
14.11. Brazil Somatostatin Analogs Market Forecast, By Treatment
14.11.1. Neuroendocrine Tumor (NET)
14.11.2. Carcinoid Syndrome
14.11.3. Acromegaly
14.11.4. Cushing’s Syndrome
14.11.5. Other
14.12. Mexico Somatostatin Analogs Market Forecast, by Type
14.12.1. Octreotide
14.12.2. Lanreotide
14.12.3. Pasireotide
14.12.4. Others
14.13. Mexico Somatostatin Analogs Market Forecast, By Treatment
14.13.1. Neuroendocrine Tumor (NET)
14.13.2. Carcinoid Syndrome
14.13.3. Acromegaly
14.13.4. Cushing’s Syndrome
14.13.5. Other
14.14. Rest of South America Somatostatin Analogs Market Forecast, by Type
14.14.1. Octreotide
14.14.2. Lanreotide
14.14.3. Pasireotide
14.14.4. Others
14.15. Rest of South America Somatostatin Analogs Market Forecast, By Treatment
14.15.1. Neuroendocrine Tumor (NET)
14.15.2. Carcinoid Syndrome
14.15.3. Acromegaly
14.15.4. Cushing’s Syndrome
14.15.5. Other
14.16. South America Somatostatin Analogs Market Attractiveness Analysis
14.16.1. By Type
14.16.2. By Treatment
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Developments

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Vehicles and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Vehicles
15.2.3.2. M&A Key Players, Forward Integration and Backward
15.2.3.3. Integration
15.3. Company Profiles: Key Players
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Sun Pharmaceutical Industries Ltd
15.3.3. Midatech Pharma PLC
15.3.4. Ipsen Pharma
15.3.5. Chiasma, Inc.
15.3.6. Peptron, Inc
15.3.7. Crinetics Pharmaceuticals
15.3.8. Dauntless Pharmaceuticals
15.3.9. Camurus AB
15.3.10. Teva Pharmaceuticals Inc.
15.3.11. Pfizer Inc.
15.3.12. Fresenius Kabi
15.3.13. Mylan N.V.
15.3.14. SAGENT Pharmaceuticals
15.3.15. Hikma Pharmaceuticals PLC
15.3.16. Recordati Rare Diseases.
15.3.17. Hybio Pharmaceutical Co., Ltd.
15.3.18. Lonza Group AG
15.3.19. Teijin Pharma Limited
15.3.20. Fresenius Kabi
16. Primary Key Insights
  • INQUIRE BEFORE BUYING